Complicated Cataracts Cases: A Multi-Disciplinary Approach 2024

Click Here to Register for the Livestream!

With the emergence of new technologies, treatments, and clinical trial results, ophthalmologists need to understand how to incorporate these advances into clinical care. We will discuss latest advances in the management of inherited and acquired ophthalmic diseases and evidence for emerging therapies and screening modalities. Both didactic and case-based educational formats will be utilized to illustrate current trends in the management of complex and routine ophthalmic patients, taking into account diagnostics as well as nonsurgical and surgical treatment.

This conference will offer a deep dive into complicated cataract cases and their intersection with other ophthalmology specialties, specifically cornea, glaucoma, and retina.

1. Evaluate newly available lens options
2. Implement the use of new technologies and devices in cataract care
3. Strategize care plans for complicated situations involving cataracts concurrent with glaucoma, corneal, and/or retinal issues
4. Educate patients on appropriate lens selection

AMA PRA Statement
Wills Eye Hospital designates this Live Activity for a maximum of 3.25 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Mitigation of Relevant Financial Relationships

In compliance with the Standards for Integrity and Independence in Accredited Continuing Education set by the Accreditation Council for Continuing Medical Education (ACCME), it is the policy of Wills Eye Hospital that the information presented at CME activities will be commercially unbiased and based upon clinical and scientific evidence. To help participants make judgments about the presence of commercial bias, Wills Eye Hospital provides information that all individuals in a position to control the content of a CME activity (including faculty, planners, reviewers or others) have disclosed about all financial relationships they have with ineligible companies. All relevant financial relationships have been mitigated.

Ineligible companies are companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Financial relationships are relevant if the educational content an individual can control is related to the business lines or products of the ineligible company. The CME activity staff at Wills Eye Hospital report no financial relationships with ineligible companies.

Member Information

Role in activity

Nature of Relationship(s) / Name of Ineligible Company(s)

John C Anhalt, MD
Wills Eye Hospital

Faculty

Nothing to disclose

Ayan Chatterjee, MD
Kremer Eye and Wills Eye

Faculty

Honoraria-Alcon (Relationship has ended)

Drew Chronister, MD
Levin Luminais Chronister Eye Associates

Faculty

Nothing to disclose

Jordan Deaner, MD
Mid Atlantic Retina, Wills Eye Hospital

Faculty

Consulting Fee-EyePoint Pharmaceuticals (Relationship has ended)|Consulting Fee-Alimera Sciences (Relationship has ended)|Consulting Fee-Genentech (Relationship has ended)|Consulting Fee-Bausch + Lomb (Relationship has ended)|Consulting Fee-Regeneron (Relationship has ended)

Kristin DiDomenico, MD
Kay, Tabas, Niknam & Didomenico ophthalmology associates

Faculty

Consulting Fee-Santen Pharmaceuticals (Relationship has ended)

Colleen Halfpenny, MD
Wills

Faculty

Nothing to disclose

Christina McGowan, MD
Wills Eye Hospital

Faculty

Nothing to disclose

Anton Orlin, MD
Weill Cornell Medical College

Faculty

Membership on Advisory Committees or Review Panels, Board Membership, etc.-Allergan (Relationship has ended)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Zeiss (Relationship has ended)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Genentech (Relationship has ended)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Apellis Pharmaceuticals (Relationship has ended)

Ravi Patel, MD, MBA
Wills Eye Hospital

Faculty

Speakers Bureau-Allergan|Speakers Bureau-Oyster Point Pharmaceuticals|Consulting Fee-Bio-Tissue|Consulting Fee-Johnson & Johnson|Grant or research support-Ocular Therapeutix (Relationship has ended)|Consulting Fee-Kala Pharmaceuticals (Relationship has ended)|Consulting Fee-Bausch + Lomb

Michael Pro, MD
Ophthalmic Partners of PA

Faculty

Nothing to disclose

Mark F Pyfer, MD
Northern Ophthalmic Associates

Faculty

Membership on Advisory Committees or Review Panels, Board Membership, etc.-Johnson & Johnson|Paid consultant-Johnson & Johnson|Independent Contractor (included contracted research)-Sight Sciences (Relationship has ended)|Speakers Bureau-Sight Sciences|Speakers Bureau-Rayner Surgical|Independent Contractor (included contracted research)-Tarsus (Relationship has ended)

David Stephens, MD
Tyson Eye

Faculty

Consulting Fee-Alcon|Speakers Bureau-Allergan|Speakers Bureau-Glaukos Corporation|Speakers Bureau-RxSight|Speakers Bureau-Lensar|Speakers Bureau-Ianterk

Janine G Tabas, MD
Kay, Tabas, Niknam, DiDomenico Ophthalmology Associates

Faculty

Nothing to disclose

Alice Williams, MD
Friedberg Eye Associates

Faculty

Nothing to disclose

Douglas Wisner, MD
Wills Eye Hospital

Faculty

Advisor-Zeiss|Advisor-Haag-Streit

Michael Wong, MD
Princeton Eye Group

Faculty

Nothing to disclose

Melissa Sieber, MD
Ophthalmic Associates

Faculty, Planner

Nothing to disclose

Brett Weinstock, MD
Friedberg Eye Associates

Faculty, Planner

Nothing to disclose

Alessandra K Intili, MD
Valley Eye Professionals

Planner

Nothing to disclose

Saturday, November 16, 2024